Olympus Corporation (7733.T) Earnings Call Transcript & Summary

Today marks an exciting milestone, sharing with you the new Olympus strategy, one that builds on our evolution as a pure-play med tech company, but also defines the next chapter with clarity and conviction. Let us begin with the world around us. Populations are aging quickly. Already, more than 40% of people are over 60. As people live longer, chronic diseases become more common among them, gastrointestinal, urological and lung cancer. These trends are driving steady demand for endoscopy-enabled care. In value terms, the market grows at about 5% a year across the application field served by Olympus. In developed markets, Japan, Europe, the United States and China, roughly 155 million endoscopy procedures are performed each year. Yet these regions represent only about 1/4 of the world's population. As access to care rises in other markets, the total number of procedures could be nearly 4x higher, around $600 million annually. What holds that potential back today are the barriers along the care pathway, lack of clinician training and infrastructure in certain markets, clinicians spending too much time on administrative work and documentation. Health care systems are under pressure. The overall cost of care keeps rising, yet in many regions, access remains limited. Overcoming these challenges will take extending endoscopy-enabled care into underserved markets, expanding it into adjacent disease areas and procedures that today rely on more invasive methods and democratizing advanced interventions such as ESD and ERCP. That's today. But now I want you to step with me into the future. A future where care looks and feels very differently for patients, clinicians and administrators. Imagine a future where endoscopy-enabled care extends its benefits to many more millions of people. The difference will be felt across the entire care ecosystem by everyone it touches. For patients, it means broader access, faster answers and less disruption. New technology will detect disease earlier and more accurately, reducing unnecessary biopsies. Diagnosis and treatment will often happen in one visit with less waiting, quicker recovery and greater peace of mind. For clinicians, workflow will be automated and the technology provided at the point of care will lessen the manual load. Procedures will become more consistent, thereby reducing a major cause of poor outcomes and freeing time for clinical judgment and patient connection. And for administrators, the future will bring increased reliability and simplicity where systems stay ready, tools are available and resources are used when and where they bring the greatest value and where efficiency and quality work together, not pull each other apart. The power of endoscopy-enabled care is already adding years to the lives of millions of people, and we envision a future where that benefit is brought to millions more. We believe Olympus is uniquely positioned to deliver on this vision. The future I just described is just beginning to dawn and a refocused Olympus is poised to make it a reality. Our global presence, long-standing partnerships with leading clinical experts and the largest installed base of endoscopy systems form the foundation that supports much of the endoscopy-enabled care worldwide. Our strategy brings together imaging platforms, therapeutic devices, digital solutions, service, training and artificial intelligence to create a seamless ecosystem that connects diagnosis, treatment and the management of capital equipment. We aim to deliver holistic support for patients, customers and hospital systems. We will bring forward the next wave of intelligent technologies from robotics to new therapeutic instruments as we build on our base, opening new opportunities to make endoscopy-enabled care more precise, more efficient and more widely available. We are investing across our entire endoscopy ecosystem to create the endosuite of the future. To accomplish this, over the next 3 years, Olympus will further strengthen our portfolio of core products, ensuring customers have the tools they need. Our planned pipeline of launches will extend our world-class leading systems and scopes to current and new regions across our care focus areas. Each of our business units has a role to play in detecting and treating diseases throughout the body, and we partner with our customers to fight those diseases. Therefore, we have selectively focused our R&D efforts to ensure faster execution on this pipeline, so customers have the full suite of products that they need from Olympus. With these near-term launches occurring, Olympus is simultaneously investing in the future, especially in 3 specific areas. First, OLYSENSE. Our latest intelligent endoscopy ecosystem is just getting started and has recently launched in both Europe and the U.S. By FY '28, we anticipate connecting up to 5% of our installed base to this cloud AI-supported platform with a gradual increase to 25% by FY '31. OLYSENSE will bring the new levels of artificial intelligence to our platforms, revolutionizing workflow, training, disease detection and eventually the standardization of complex procedures. Second, Endoluminal robotics is a top priority, starting with our recently created joint venture, Swan EndoSurgical. We have charted an excited path for endoluminal robotics, and we will add additional capabilities in this space to accelerate the impact of this technology that can have as part of our ecosystem. Certainly, robotic technology has the potential to set a new standard, reaching diseases that were once unreachable with shorter procedure times and fewer complications. It could, for instance, democratize therapeutic procedures and enable flexible ESD throughout the colon. It's predicted that this could be a USD 2 billion market in the U.S. alone by 2040. Our third focus area is advanced diagnostic and therapeutic solutions. OLYSENSE, AI, robotics may enable us to reach and diagnose disease with precision and efficiency, but we must be able to treat when we get there. Through R&D, partnerships and acquisitions, we plan to constantly expand our therapeutic technologies and clinical application areas to deliver more interconnected, advanced and cost-efficient solutions, equipping clinicians to more effectively fight disease across our clinical and disease focus areas. Ultimately, what this strategy translates to is better care for millions of patients. At Olympus, we are shaping the next era of endoscopy-enabled care, one where technology and human expertise come together seamlessly to advance health with greater precision, simplicity and reach. We see a future where disease is found earlier and treated more gently, often in a single minimally invasive procedure. More conditions will be treated endoscopically, preserving organs, shortening recovery and restoring confidence in less time. Care becomes more connected and more intelligent. Devices, data, robotics form one adaptive ecosystem, learning from every procedure, refining every workflow and empowering every clinical decision. As technology grows quieter, more intuitive, clinicians gain steadier, more consistent support. Systems stay ready and resources are deployed where they bring the greatest value and efficiency and quality advance together. This is the future Olympus is building, where endoscopy-enabled care extends life, enhances its quality and sets a new standard for what minimally invasive medicine can achieve. That will be the very purpose of our endeavors. To bring this vision to life, we're introducing a new operating model to support growth with greater focus and discipline. Our new model simplifies what has grown complex and aligns our structure with the precision we aim to deliver in care. We will move from a region-led model to a simpler division-led matrix built around customer centricity and clinical needs. This shift will make us faster, more decisive and more consistent across functions and geographies with streamlined governance and better decision-making. In the near term, we believe these structural changes will deliver about JPY 24 billion of run rate savings and a net reduction of roughly 2,000 positions as we simplify our organization, reduce hierarchy and widen spans of control to increase agility and accountability. Looking further ahead, we will build on these foundations. We will strengthen our supply chain, align processes end-to-end and refine the operating model we've put in place. It will enable sustained quality and regulatory compliance while accelerating productivity and margin improvement. Data and AI will support this progress, bringing greater consistency and speed across everything we do. Throughout this period, we will continuously focus on talent and capability building investments that strengthen our foundation. We believe that the combination of our growth and operating model transformation plan ensures we deliver on our promise to patients and health care providers. And likewise, for our shareholders with a balanced financial plan for revenue acceleration, efficiency gains and margin expansion. In this strategic plan period, we anticipate that our 3%, 4%, 5% revenue plan will have Olympus growing with an estimated 5% year-on-year revenue growth by FY '29. Our projection is underpinned by clear drivers in our current pipeline, we also plan to deliver around 100 basis point gains of margin improvement every year, substantiated by high-impact near-term restructuring and long-term transformations. Completing our financial picture, Olympus plans to target steady improvement of free cash flow over the strategic plan period, demonstrating that we are not only growing earnings, but we're converting that growth into cash-based value. We intend to deploy our capital dynamically throughout the strategic plan to enable reinvestment in innovation, dividends, share buybacks and M&A. To summarize on a single page, we can put this all together, our vision, our pipeline, our bold investments and our new operating model, we will enter the next era where Olympus becomes the place where purpose meets performance. Our vision will be achieved through these 3 strategic pillars: innovation-driven growth, simplicity and accountability. As outlined, innovation-driven growth is at the heart of what we'll do. Leveraging the world's largest GI installed base, we're focused on key product launches with an advanced ecosystem of technologies that propel us to the future of endoscopy-enabled care that I outlined. Included within innovation-driven growth is expanding our presence and ensuring access to our markets in China and other emerging markets to drive growth. Lastly, to gain access to innovation, technology and capabilities, we plan to leverage M&A and partnerships, ensuring the fastest and best path forward are utilized. The second pillar of our strategy, simplicity should ensure a strong operating foundation by simplifying the company. Beginning this year, short-term restructuring should drive organizational health and readiness, while long-term transformations will fundamentally change how we operate, making us a leaner organization operating at med-tech benchmark cost levels. This brings me to our third pillar, accountability. We will take this opportunity now to create a high-performance culture, moving to an environment where excellence and execution are rewarded. This has become a critical part of our strategy because the better we operate the business, the more patients we serve. And a patient-first mindset is fundamental to us. It's the very air we breathe, and we are committed to embedding quality and patient safety into every step of our work. We will continue our commitments to ESG, and we will be implementing an Olympus management system to help us deliver on our overall plan. These 3 strategic pillars are anchored on our purpose and our values, and those aren't changing. Our purpose and values resonate very deeply with me and all the employees at Olympus. If we execute our strategy successfully, we believe our ambitions will be realized. Our financial ambitions are also clear: a 3%, 4%, 5% growth plan with 100 basis points of margin expansion targeted each year and double-digit earnings per share growth. The strategy is not just what we say, it's what we do. Everyone at Olympus will have this framework, and each of the strategic priorities shown here will have specific action plans, resource alignment and accountability measures to execute. Now some may characterize this plan as conservative. Others may characterize it as aggressive given our history, but our leadership teams believes this is an achievable plan that propels us forward towards improved growth and profitability. Our vision is compelling, and our strategy is pragmatic. We focus on innovation-driven growth, simplify Olympus and place a premium on accountability and execution. In doing so, we believe we will develop innovations that will set new standards in endoscopy-enabled care and deliver better care for millions of patients around the world. Now I'd like to share a video that let's you experience first hand the future of endoscopy-enabled care. [Presentation]